LV12283A - Naaladazes kompozicijas un to pielietojums dzivnieku glutamata vielmainas anomalijas arstesanai un neironu aktivitates ietekmesanai - Google Patents

Naaladazes kompozicijas un to pielietojums dzivnieku glutamata vielmainas anomalijas arstesanai un neironu aktivitates ietekmesanai

Info

Publication number
LV12283A
LV12283A LV990049A LV990049A LV12283A LV 12283 A LV12283 A LV 12283A LV 990049 A LV990049 A LV 990049A LV 990049 A LV990049 A LV 990049A LV 12283 A LV12283 A LV 12283A
Authority
LV
Latvia
Prior art keywords
naaladase
gluten
anomalies
animal
compositions
Prior art date
Application number
LV990049A
Other languages
English (en)
Latvian (lv)
Inventor
Barbara S Slusher
Paul F Jackson
Kevin L Tays
Keith M Maclin
Original Assignee
Guilford Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/718,703 external-priority patent/US5824662A/en
Priority claimed from US08/842,360 external-priority patent/US6054444A/en
Priority claimed from US08/863,624 external-priority patent/US6046180A/en
Priority claimed from US08/858,985 external-priority patent/US6025344A/en
Priority claimed from US08/884,479 external-priority patent/US6017903A/en
Application filed by Guilford Pharm Inc filed Critical Guilford Pharm Inc
Publication of LV12283A publication Critical patent/LV12283A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/665Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/30Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/301Acyclic saturated acids which can have further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808Acyclic saturated acids which can have further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3826Acyclic unsaturated acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4071Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4075Esters with hydroxyalkyl compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44Amides thereof
    • C07F9/4461Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4465Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/58Pyridine rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LV990049A 1996-09-27 1999-03-25 Naaladazes kompozicijas un to pielietojums dzivnieku glutamata vielmainas anomalijas arstesanai un neironu aktivitates ietekmesanai LV12283A (lv)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US08/718,703 US5824662A (en) 1996-09-27 1996-09-27 Treatment of global and focal ischemia using naaladase inhibitors
US08/842,360 US6054444A (en) 1997-04-24 1997-04-24 Phosphonic acid derivatives
US08/863,624 US6046180A (en) 1996-06-17 1997-05-27 NAALADase inhibitors
US08/858,985 US6025344A (en) 1996-06-17 1997-05-27 Certain dioic acid derivatives useful as NAALADase inhibitors
US08/884,479 US6017903A (en) 1996-09-27 1997-06-27 Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
PCT/US1997/014344 WO1998013046A1 (en) 1996-09-27 1997-08-15 Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals

Publications (1)

Publication Number Publication Date
LV12283A true LV12283A (lv) 1999-06-20

Family

ID=27542138

Family Applications (1)

Application Number Title Priority Date Filing Date
LV990049A LV12283A (lv) 1996-09-27 1999-03-25 Naaladazes kompozicijas un to pielietojums dzivnieku glutamata vielmainas anomalijas arstesanai un neironu aktivitates ietekmesanai

Country Status (16)

Country Link
US (1) US6413948B1 (ja)
EP (1) EP1005348A1 (ja)
JP (1) JP2002514184A (ja)
KR (1) KR20000036227A (ja)
CN (1) CN1230889A (ja)
AU (1) AU733880B2 (ja)
CA (1) CA2264043A1 (ja)
CZ (1) CZ60499A3 (ja)
HU (1) HUP0001062A3 (ja)
IL (1) IL128718A0 (ja)
LV (1) LV12283A (ja)
NO (1) NO991387L (ja)
NZ (1) NZ334780A (ja)
PL (1) PL332413A1 (ja)
TR (1) TR199901173T2 (ja)
WO (1) WO1998013046A1 (ja)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070782B1 (en) 1992-11-05 2006-07-04 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US7105159B1 (en) 1992-11-05 2006-09-12 Sloan-Kettering Institute For Cancer Research Antibodies to prostate-specific membrane antigen
US6953668B1 (en) 1992-11-05 2005-10-11 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US6569432B1 (en) * 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
AU717937B2 (en) 1995-02-24 2000-04-06 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
US20040253246A1 (en) * 1996-02-23 2004-12-16 Israeli Ron S. Prostate-specific membrane antigen and uses thereof
US6071965A (en) * 1996-06-17 2000-06-06 Guilford Pharmaceuticals Inc. Phosphinic alkanoic acid derivatives
ID20347A (id) * 1997-05-27 1998-12-03 Guilford Pharm Inc Inhibitor aktifitas enzim naaladase
US6159958A (en) * 1997-08-14 2000-12-12 The United States Of America As Represented By The Secretary Of The Army Treatment or prophylaxis of retinal pathology and spinal cord injury
IL134619A0 (en) * 1997-08-18 2001-04-30 Univ Kingston Phosphono-carboxylate compounds for treating amyloidosis
AU3822902A (en) * 1997-08-18 2002-06-27 Queen's University At Kingston Phosphono-carboxylate compounds for treating amyloidosis
US6329356B1 (en) 1998-04-10 2001-12-11 Neurochem, Inc. Phosphono-carboxylate compounds for treating amyloidosis
US6444657B1 (en) * 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
US6528499B1 (en) 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
ATE298343T1 (de) 1999-04-28 2005-07-15 Univ Georgetown Ligande für metabotropische glutamat-rezeptoren
US6562836B1 (en) 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
US6228888B1 (en) * 1999-07-01 2001-05-08 Guilford Pharmaceuticals Inc. Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors
AU781218B2 (en) 1999-08-16 2005-05-12 Revaax Pharmaceuticals, Llc Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of behavioral diseases
WO2001091738A2 (en) * 2000-05-30 2001-12-06 Guilford Pharmaceuticals Inc. Naaladase inhibitors for treating amyotrophic lateral sclerosis
WO2001092273A2 (en) * 2000-05-30 2001-12-06 Guilford Pharmaceuticals Inc. Benzenedicarboxylic acid derivatives
CA2436408A1 (en) 2001-02-07 2002-12-12 Beth Israel Deaconess Medical Center Modified psma ligands and uses related thereto
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
CA2464239C (en) 2001-10-23 2016-07-12 Psma Development Company, L.L.C. Psma antibodies and protein multimers
WO2003057670A2 (en) * 2001-12-28 2003-07-17 Guilford Pharmaceuticals Inc. Indoles as naaladase inhibitors
JP4773951B2 (ja) * 2003-03-03 2011-09-14 エーザイ インコーポレーテッド チオラクトン
SG155939A1 (en) 2004-09-17 2009-10-29 Idenix Pharmaceuticals Inc Phosphoindoles as hiv inhibitors
CA2900876A1 (en) 2004-12-22 2006-08-17 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
WO2006125324A1 (en) * 2005-05-27 2006-11-30 Queen's University At Kingston Treatment of protein folding disorders
EA016267B1 (ru) 2006-09-29 2012-03-30 Айденикс Фармасьютикалз, Инк. Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv
KR101443573B1 (ko) 2006-10-12 2014-11-03 비에이치아이 리미티드 파트너쉽 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클
HUE039199T2 (hu) 2006-11-08 2018-12-28 Molecular Insight Pharm Inc Glutaminsav heterodimerjei
EP2706057B1 (en) 2008-12-05 2016-04-20 Molecular Insight Pharmaceuticals, Inc. Bis(imidazolyl)compounds and radionuclide complexes
AU2010260195B2 (en) 2009-06-15 2014-11-20 Molecular Insight Pharmaceuticals, Inc. Process for production of heterodimers of glutamic acid
WO2012082903A2 (en) * 2010-12-14 2012-06-21 The Johns Hopkins University Treatment of cognitive impairment in a subject with a neurological autoimmune disease
AU2013207486A1 (en) 2012-01-06 2014-08-21 Molecular Insight Pharmaceuticals Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX
ES2648096T3 (es) 2013-01-14 2017-12-28 Molecular Insight Pharmaceuticals, Inc. Radiofármacos a base de triazina y agentes de radioformación de imágenes

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162512A (en) 1982-03-09 1992-11-10 Cytogen Corporation Amine derivatives of anthracycline antibodies
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4950738A (en) 1984-09-13 1990-08-21 Cytogen Corporation Amine derivatives of anthracycline antibiotics
US5140104A (en) 1982-03-09 1992-08-18 Cytogen Corporation Amine derivatives of folic acid analogs
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
FR2590674B1 (fr) 1985-11-25 1989-03-03 Inst Nat Sante Rech Med Nouveaux reactifs de diagnostic
US4906779A (en) 1986-07-10 1990-03-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists
US5093525A (en) 1986-07-10 1992-03-03 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists
US5190976A (en) 1986-07-10 1993-03-02 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And University Of Oregon N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists
JP2608550B2 (ja) * 1986-10-17 1997-05-07 株式会社 片山化学工業研究所 軟水ボイラの防食処理方法
US5143908A (en) * 1986-11-05 1992-09-01 Merck & Co., Inc. Antibacterial agents and potentiators of carbapenem antibiotics
US4806543A (en) 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury
CA1305177C (en) 1987-06-30 1992-07-14 Yasufumi Ohfune Carboxycyclopropylglycine and process for producing the same
US4918064A (en) 1987-10-21 1990-04-17 G. D. Searle & Co. Phenyl glycines for use in reducing neurotoxic injury
US5871472A (en) 1987-11-17 1999-02-16 Brown University Research Foundation Planting devices for the focal release of neuroinhibitory compounds
DE3854991T2 (de) 1987-11-27 1996-07-18 Eisai Co Ltd Cyclische Amine und pharmakologische Verbindungen
US5196439A (en) 1987-11-27 1993-03-23 Eisai Co., Ltd. Piperidine compounds useful to treat cerebrovascular diseases
US4937183A (en) 1988-02-03 1990-06-26 Cytogen Corporation Method for the preparation of antibody-fragment conjugates
US5047227A (en) 1988-02-08 1991-09-10 Cytogen Corporation Novel and improved antibodies for site specific attachment of compounds
US5177109A (en) 1988-05-16 1993-01-05 G. D. Searle & Co. 2-amino-4,5-methyleneadipic acid compounds for treatment of CNS disorders
EP0342558B1 (en) 1988-05-16 1994-02-02 G.D. Searle & Co. 2-amino-4,5-methyleneadipic acid compounds for treatment of CNS disorders
IT1217603B (it) 1988-05-16 1990-03-30 Uni Degli Studi Perugia Derivati di acido 2 ammino 4,5 metilen adipico attivi sul sistema nervoso centrale
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US4966999A (en) 1988-06-07 1990-10-30 Cytogen Corporation Radiohalogenated compounds for site specific labeling
FI93838C (fi) 1988-06-28 1995-06-12 Novo Nordisk As Menetelmä uusien terapeuttisesti käyttökelpoisten 7,8-dihydroksi-1H-imidatso- ja pyratsolo/3,4-f/kinoksaliinijohdannaisten valmistamiseksi
DK160941C (da) 1988-06-28 1991-10-21 Novo Nordisk As Kondenserede 2,3-dihydroxypyraziner, fremgangsmaade til deres fremstilling og farmaceutiske praeparater, hvori forbindelserne indgaar
DE3839659A1 (de) 1988-11-24 1990-05-31 Boehringer Ingelheim Kg Verwendung von benzomorphanen zur zytoprotektion
FR2640624B1 (fr) 1988-12-15 1994-08-12 Rhone Poulenc Sante Medicaments a base de derives de la benzothiazolamine-2, nouveaux derives et leur preparation
FR2649703B1 (fr) 1989-07-13 1991-11-22 Rhone Poulenc Sante Derives d'imino-2 polyfluoroalcoxy-6 benzothiazole, leurs procedes de preparation et les medicaments les contenant
FR2649705B2 (fr) 1989-07-13 1994-09-23 Rhone Poulenc Sante Medicaments a base de derives de la benzothiazolamine-2, nouveaux derives et leur preparation
DE68903484T2 (de) 1988-12-15 1993-03-18 Rhone Poulenc Sante 2-imino-6-polyfluoralkoxy-benzothiazol-derivate, verfahren zu deren herstellung und arzneimittel, die sie enthalten.
FR2640622B1 (fr) 1988-12-15 1991-03-22 Rhone Poulenc Sante Derives de l'imino-2 benzothiazoline, leurs procedes de preparation et les medicaments les contenant
FR2649701B2 (fr) 1988-12-15 1991-11-22 Rhone Poulenc Sante Derives d'imino-2 benzothiazoline, leurs procedes de preparation et les medicaments les contenant
EP0374041B1 (fr) 1988-12-15 1992-06-17 Rhone-Poulenc Sante Médicaments à base de dérivés de la benzothiazolamine-2, dérivés et leur préparation
US5236940A (en) 1988-12-15 1993-08-17 Rhone-Poulenc Sante Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation
US5196510A (en) 1988-12-29 1993-03-23 Cytogen Corporation Molecular recognition units
US4994446A (en) 1989-01-03 1991-02-19 Ramot - University Authority For Applied Research And Industrial Development Ltd. Drug system
US5011834A (en) 1989-04-14 1991-04-30 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon PCP receptor ligands and the use thereof
FR2649702B1 (fr) 1989-07-13 1991-11-22 Rhone Poulenc Sante Derives d'alkylimino-2 benzothiazoline, leurs procedes de preparation et les medicaments les contenant
CA2069912A1 (en) 1989-10-25 1991-04-26 A. Richard Chamberlin Method of inhibiting the transport of l-glutamate
US5521215A (en) 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
IL92238A (en) 1989-11-07 1995-07-31 Yissum Res Dev Co ADMN blocking product containing tetrahydrocannabinol history, several new tetrahydrocannabinol histories and process for their preparation
US5284867A (en) 1989-11-07 1994-02-08 Yissum Research Development Company Of The Hebrew University In Jerusalem NMDA-blocking pharmaceutical compositions
IT1238346B (it) 1989-11-14 1993-07-13 Gangliosidi modificati e loro derivati funzionali.
FR2662160B1 (fr) 1990-05-18 1992-07-24 Rhone Poulenc Sante Derives d'alkylthio-3 propyl-3 benzothiazoline leur preparation et les medicaments les contenant.
US5130330A (en) 1990-01-31 1992-07-14 G. D. Searle & Co. Nitrogen-containing cyclohetero cycloalkylaminoaryl derivatives for cns disorders
DK0517852T3 (da) 1990-03-02 2002-10-07 Oregon State Tri- og tetrasubstituerede guanidinerog disses anvendelse som excitatoriske aminosyre-antagonister
US5262568A (en) 1990-03-02 1993-11-16 State Of Oregon Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
US5336689A (en) 1990-03-02 1994-08-09 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
FR2662694A1 (fr) 1990-06-05 1991-12-06 Rhone Poulenc Sante Derives du benzoselenazole, leur preparation et les medicaments les contenant.
FR2662695A1 (fr) 1990-06-05 1991-12-06 Rhone Poulenc Sante Amino-2 polyfluoroalcoxy-6 benzoselenazoles, leur preparation et les medicaments les contenant.
FR2663029B1 (fr) 1990-06-07 1992-07-31 Rhone Poulenc Sante Derives de benzothiazole, leur preparation et les medicaments les contenant.
JPH0474197A (ja) 1990-07-12 1992-03-09 Naoyoshi Suzuki 新規な免疫調整生理活性ペプチド
US5089517A (en) 1990-08-03 1992-02-18 The Board Of Trustees Of The Leland Stanford Junior University Neuroprotection by indolactam v and derivatives thereof
US5145862A (en) 1990-08-16 1992-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of resisting neurodegenerative disorders
WO1992004023A1 (en) 1990-09-10 1992-03-19 Shug Austin L Composition and method for protecting the heart during reperfusion
US5158976A (en) 1990-10-29 1992-10-27 The Children's Medical Center Corporation Controlling glutamine/glutamate related neuronal injury
DE69132340T2 (de) 1990-11-06 2001-02-08 Yamanouchi Pharmaceutical Co., Ltd. Kondensiertes pyrazinderivat
JPH06506455A (ja) 1991-02-08 1994-07-21 ケンブリッジ・ニューロサイエンス・インコーポレイテッド 神経伝達物質放出調節剤としてのグアニジン置換体及びその誘導体ならびに神経伝達物質放出遮断物質を同定するための新規な方法
US5135080A (en) 1991-04-30 1992-08-04 E. I. Du Pont De Nemours And Company Stand up fork lift truck safety net
JP2632754B2 (ja) 1991-05-21 1997-07-23 塩野義製薬株式会社 脳内グルタミン酸遊離抑制剤
FR2678619B1 (fr) 1991-07-04 1993-09-17 Rhone Poulenc Rorer Sa Derives de 1,2,4-thiadiazolo[3,4-b]benzothiazole, leur preparation et les medicaments les contenant.
US5502166A (en) 1992-02-26 1996-03-26 Mitsubishi Chemical Corporation NMDH receptor proteins and genes encoding the same
US5326856A (en) 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
DE4212529A1 (de) 1992-04-10 1993-10-14 Schering Ag Verwendung von µ-Carbolinen als nicht-kompetitive Glutamat-Antagonisten
USH1312H (en) 1992-05-28 1994-05-03 Cytogen Corporation Method for the preparation of gyk-dtpa
AU4540193A (en) 1992-06-17 1994-01-04 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Method of treating and protecting against central nervous system ischemia, hypoxia, degeneration, and trauma with a 5-aminocarbonyl-sh-dibenzo{a,d}cyclohepten-5,10-imine
IT1260156B (it) 1992-08-03 1996-03-28 Fidia Spa Derivati dell'acido neuraminico
US5489525A (en) 1992-10-08 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies to prostate cells
EP1757694A3 (en) 1992-11-05 2008-02-27 Sloan Kettering Institute For Cancer Research Prostate-specific membrane antigen
US5356902A (en) 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5319095A (en) 1992-12-04 1994-06-07 Eli Lilly And Company Synthesis of kainic acid
US5438130A (en) 1993-01-15 1995-08-01 Cambridge Neuroscience, Inc. Fucosylated guanosine disulfates as excitatory amino acid antagonists
US5622965A (en) 1993-03-12 1997-04-22 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon 4-hydroxy-3-nitro-1,2-dihydroquinolin-2-ones and the use thereof as excitatory amino acid and glycine receptor antagonists
JP3209377B2 (ja) 1993-04-19 2001-09-17 花王株式会社 吸収性物品の製造方法
DK69693D0 (da) 1993-06-14 1993-06-14 Neurosearch As Farven lilla
FR2707880B1 (fr) 1993-06-30 1995-10-06 Rhone Poulenc Rorer Sa Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodégénératives.
US5434159A (en) 1993-09-14 1995-07-18 Sterling Winthrop Inc. 6,11-cyclyl-1,2,3,4,5,6,11,11a-octahydrobenzo[b]quinolines and compositions and method of use thereof
US5449761A (en) 1993-09-28 1995-09-12 Cytogen Corporation Metal-binding targeted polypeptide constructs
US5491241A (en) 1993-10-18 1996-02-13 Eli Lilly And Company Bicyclic intermediates for excitatory amino acid receptor antagonists
US5495042A (en) 1993-11-04 1996-02-27 Cytogen Corporation Non-alkaline purification of aminophosphonic acids
US5459037A (en) 1993-11-12 1995-10-17 The Scripps Research Institute Method for simultaneous identification of differentially expressed mRNAs and measurement of relative concentrations
US5576323A (en) 1993-12-03 1996-11-19 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5500420A (en) * 1993-12-20 1996-03-19 Cornell Research Foundation, Inc. Metabotropic glutamate receptor agonists in the treatment of cerebral ischemia
US6274330B1 (en) 1993-12-30 2001-08-14 Zymogenetics, Inc. L-AP4 sensitive glutamate receptors
PL316239A1 (en) 1994-03-14 1997-01-06 Novo Nordisk As Heterocyclic compounds, their production and application
DE4410822A1 (de) 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
US5489717A (en) 1994-07-08 1996-02-06 Warner-Lambert Company Glutamate (NMDA) receptor antagonists
PL182285B1 (pl) 1994-08-12 2001-12-31 Lilly Co Eli Syntetyczne aminokwasy oraz ich estry i srodki farmaceutyczne je zawierajace PL PL PL PL PL PL PL
US5750566A (en) 1994-08-12 1998-05-12 Eli Lilly And Company Synthetic excitatory amino acids
TR199501070A2 (tr) 1994-08-31 1996-06-21 Lilly Co Eli Dihidro-2,3-benzodiazepin türevinin kristalli bicimi.
FR2726271B1 (fr) 1994-10-26 1996-12-06 Rhone Poulenc Rorer Sa Derives de 6-polyfluoroalcoxy-2-aminobenzothiazole
US5473077A (en) 1994-11-14 1995-12-05 Eli Lilly And Company Pyrrolidinyl di-carboxylic acid derivatives as metabotropic glutamate receptor agonists
US5795877A (en) 1996-12-31 1998-08-18 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US5804602A (en) 1996-06-17 1998-09-08 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
US5977090A (en) 1996-09-27 1999-11-02 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors
US5824662A (en) 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
US5863536A (en) 1996-12-31 1999-01-26 Guilford Pharmaceuticals Inc. Phosphoramidate derivatives
US5672592A (en) 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
JP3170491B2 (ja) 1999-03-29 2001-05-28 松下電送システム株式会社 画像通信装置及びサーバ装置並びに能力交換方法
JP3762214B2 (ja) 2000-11-28 2006-04-05 株式会社エヌ・ティ・ティ・ドコモ 位置登録制御方法、移動通信網および通信端末

Also Published As

Publication number Publication date
HUP0001062A3 (en) 2001-09-28
US6413948B1 (en) 2002-07-02
TR199901173T2 (xx) 1999-07-21
KR20000036227A (ko) 2000-06-26
CZ60499A3 (cs) 1999-08-11
IL128718A0 (en) 2000-01-31
JP2002514184A (ja) 2002-05-14
AU4067797A (en) 1998-04-17
NZ334780A (en) 2000-12-22
CN1230889A (zh) 1999-10-06
AU733880B2 (en) 2001-05-31
PL332413A1 (en) 1999-09-13
CA2264043A1 (en) 1998-04-02
NO991387L (no) 1999-05-27
NO991387D0 (no) 1999-03-22
WO1998013046A1 (en) 1998-04-02
EP1005348A1 (en) 2000-06-07
HUP0001062A2 (hu) 2001-05-28

Similar Documents

Publication Publication Date Title
LV12283A (lv) Naaladazes kompozicijas un to pielietojums dzivnieku glutamata vielmainas anomalijas arstesanai un neironu aktivitates ietekmesanai
IT1285002B1 (it) Composizione antiparassitaria per il trattamento e la protezione di animali da compagnia
SE7805851L (sv) Apparat for uppretthallande av den negativa potentialen vid celler hos menniskor, djur och plantor
LV11895A (lv) 4-benzoilpirazola atvasinajumi un to pielietojums par herbicidiem
FI973828A0 (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
DE69836878D1 (de) Haarwuchszusammensetzungen und deren Verwendungen
PT902789E (pt) Derivados de androsteno
FI990171A (fi) Uusia yhdisteitä ja koostumuksia tryptaasiaktiivisuuden liittyvien tautien hoitamiseksi
BR9707252A (pt) Composições para o cuidado com tecidos incluindo poliolefinas dispersáveis e métodos para usar as mesmas
ATA11989A (de) Mittel zur vorbeugung gegen und behandlung von parodontopathien
GB2319725A8 (en) Extracting particles produced by the treating of human or animal nails
DE68913739D1 (de) Kosmetische und hautbehandlungs-zusammensetzungen.
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
TR200100637T2 (tr) Yeni doğal ürün türevleri
DK0613368T3 (da) Hudregenererende kosmetisk sammensætning
DE69822276D1 (de) Kräuter formulierung mit therapeutischer und kosmetischer verwendung zur behandlung von allgemeinen hauterkrankungen
BR9709930A (pt) Composto composição farmacêutica uso de um composto e processos para tratamento de um indivíduo humano ou animal e para preparação de um composto
DE69720410D1 (de) Therapeutisches Mittel zur Behandlung hartnäckiger Hundedermatitis
BR9702075A (pt) Derivados de uréida biologicamente ativos úteis no tratamento de esclerose múltipla
DE69112718D1 (de) Verfahren und Zusammensetzung zur Behandlung von tierischen Exkrementen.
FR2719480B1 (fr) Compositions pharmaceutiques destinées à prévenir et/ou traiter l'expression du comportement de couvaison chez les oiseaux et plus particulièrement chez la dinde et leurs procédés de préparation.
FR2594690B1 (fr) Compositions regeneratrices et stimulantes du derme
ATA539879A (de) Mittel zur bindung und sanierung von animalen, biologisch ausgesonderten schlackenprodukten
DE59708286D1 (de) Verwendung von wirkstoffmischungen, enthaltend phytostenole und/oder phytostenolester und potenzierungsmittel zur herstellung von hypocholesterinämischen mitteln
DE69110892D1 (de) Einschicht-trockene lichtempfindliche zusammensetzung für behandlung und anstrichverfahren.